Drug Profile
NJH 395
Alternative Names: Immune stimulator antibody conjugate; NJH395Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV)